PT-141 Adverse Events: What FDA Data Shows
Melanocortin Safety
40%
Nausea rate in bremelanotide-treated women across integrated phase 3 trials, versus 1.3% on placebo.
Clayton et al., Journal of Women's Health, 2022
Clayton et al., Journal of Women's Health, 2022
View as imageForty percent. That is the nausea rate the FDA reviewed when it approved bremelanotide (brand name Vyleesi) in June 2019 for premenopausal women with hypoactive sexual desire disorder (HSDD).[1] For anyone searching for a complete breakdown of PT-141 side effects, the clinical development program behind this approval is the only large-scale human dataset that exists. It spans 3,500 subjects across 43 completed studies, and the melanocortin peptide safety profile that emerged is worth examining in detail. This article breaks down the adverse event data from every phase of bremelanotide's clinical development, including the numbers the approval summaries leave out.
Key Takeaways
- Nausea occurred in 40.0% of bremelanotide-treated women versus 1.3% on placebo in integrated phase 3 data (Clayton et al., 2022)
- Flushing affected 20.3% of treated subjects, headache 11.3%, and injection site reactions 5.4% (Clayton et al., 2022)
- Blood pressure rose transiently by a mean 2.8 mmHg systolic at 4-8 hours post-dose, returning to baseline by 12-24 hours (White et al., 2017)
- Focal hyperpigmentation occurred in over one-third of subjects dosed daily for 16 consecutive days, but in only 1% at label-recommended dosing (Clayton et al., 2022)
- No deaths occurred across the entire clinical development program, and serious adverse events were rare (Clayton et al., 2022)
- During the 52-week open-label extension, 40.4% still reported nausea but no new safety signals emerged (Simon et al., 2019)
The Clinical Trial Database Behind the Approval
Bremelanotide's safety dataset is unusually large for a peptide drug. The full clinical development program included 43 completed studies enrolling 3,500 subjects across phases 1 through 3.[1] The pivotal evidence came from two identical phase 3 trials, RECONNECT studies 301 and 302 (NCT02333071 and NCT02338960), which randomized 1,267 premenopausal women with HSDD to bremelanotide 1.75 mg subcutaneous injection or placebo for 24 weeks.[2]
The safety population from the integrated double-blind portion comprised 1,247 women. Most participants were white (85.6%), from U.S. sites (96.6%), with a mean age of 39 years.[2] This demographic narrowness is a limitation: adverse event rates in other populations remain largely unstudied.
A 52-week open-label extension followed. Of the 856 eligible women who completed the core phase, 684 enrolled in the extension, and 272 completed it.[3] That completion rate (39.8% of those who enrolled) is notable. The most common reason for discontinuation was not adverse events but lack of efficacy, though nausea drove a meaningful share of dropouts.
Nausea: The Dominant Adverse Event
Nausea is the defining tolerability problem for bremelanotide. In the integrated phase 3 data, 40.0% of bremelanotide-treated women reported nausea versus 1.3% on placebo.[1] Nausea was also the most common reason for discontinuation during both the double-blind and open-label phases.
Onset typically occurred within one hour of injection, with a median duration of approximately two hours.[5] The incidence was highest with the first dose and decreased with subsequent administrations, though it never disappeared entirely. In the 52-week open-label extension, 40.4% of women still reported nausea as a treatment-related adverse event.[3]
Clayton et al. (2016) had observed this pattern in the earlier dose-finding trial, where nausea was dose-dependent and most pronounced at the 1.75 mg subcutaneous dose that was ultimately selected for phase 3.[4] The mechanism likely involves melanocortin receptor activation in the area postrema, a brain region outside the blood-brain barrier that triggers the vomiting reflex.
Anti-emetics (ondansetron, for example) can reduce the nausea, but the FDA label does not mandate pre-treatment with anti-nausea medication. Mayer and Lynch (2020) noted in their drug review that the high nausea rate may limit real-world adherence beyond what clinical trial data capture.[5]
Other Common PT-141 Side Effects: Flushing, Headache, and Injection Site Reactions
After nausea, the next most common adverse events were flushing (20.3% vs. 1.3% placebo), headache (11.3% vs. 1.9%), and injection site reactions (5.4% vs. 0.5%).[1]
Additional reported events in the phase 3 program included vomiting (4.8%), cough (3.3%), fatigue (3.2%), hot flashes (2.7%), paresthesia (2.6%), dizziness (2.2%), and nasal congestion (2.1%).[5] The flushing is consistent with melanocortin receptor activation in vascular smooth muscle and is pharmacologically expected for this class.
Cipriani et al. (2023) summarized the overall picture: adverse events were mostly mild to moderate, and bremelanotide appeared "moderately safe and well-tolerated" apart from the nausea problem.[6] That said, the dropout rate from the bremelanotide group during the double-blind phase was 30%, versus 13% on placebo.[1] The tolerability gap was real enough to push nearly one in three treated women out of the trials.
Blood Pressure: Small, Transient, But Measurable
Bremelanotide causes transient blood pressure increases through its action on melanocortin receptors in the cardiovascular system. This is the same pharmacological mechanism that links melanocortin peptides to blood pressure effects across the class.
White et al. (2017) conducted a dedicated ambulatory blood pressure monitoring (ABPM) study that provides the most detailed hemodynamic data. Mean peak increases of 2.8 mmHg in systolic blood pressure occurred between 4 and 8 hours post-dose, with mean peak diastolic increases of 2.7 mmHg at 0 to 4 hours.[7] Heart rate decreased by a mean of 0.5 beats per minute. By 12 to 24 hours post-dose, blood pressure values had returned to pre-dose levels.
These changes were statistically significant but classified as not clinically important in the overall population. The FDA label reflects this with a contraindication for uncontrolled hypertension and cardiovascular disease, not for controlled hypertension.[1]
The limitation is clear: the phase 3 trials excluded women with uncontrolled cardiovascular disease, so the behavior of bremelanotide in that population is genuinely unknown. The ABPM data come from a relatively healthy cohort. Whether a 2.8 mmHg systolic rise matters in someone with a baseline of 155/95 is a different question than whether it matters at 120/80.
Hyperpigmentation: Dose-Dependent and Potentially Permanent
Bremelanotide activates melanocortin 1 receptors (MC1R) on melanocytes, the same pathway that connects skin pigment to sexual arousal in the melanocortin system. Focal hyperpigmentation of the face, gums, and breasts is the most distinctive adverse event specific to this drug class, and it separates bremelanotide from most other peptide therapeutics.
At the FDA-approved dosing (no more than 8 doses per month), focal hyperpigmentation was reported in approximately 1% of treated subjects versus 0% on placebo.[1] That rate climbed dramatically with more frequent dosing: more than one-third of subjects who received up to 16 consecutive daily doses developed hyperpigmentation.[1]
The FDA label carries a specific warning: the hyperpigmentation may not resolve after discontinuation. This irreversibility distinguishes it from most peptide adverse events, which are pharmacologically reversible once the drug clears. The darkening tends to appear on the face, gingiva, and breasts, areas with higher melanocyte density.
The Melanotan II risk profile shares this pigmentation concern through the same MC1R mechanism. Melanotan II has a broader receptor profile, but the dermatological signal is consistent across melanocortin agonists. Melanotan II side effect data shows even higher pigmentation rates, likely because unregulated use involves much higher cumulative doses.
Drug Interactions: Limited But Notable
Bremelanotide has a narrow drug interaction profile. Clayton et al. (2017) conducted a dedicated phase 1 study of bremelanotide co-administered with ethanol in 24 healthy participants. At intranasal doses equivalent to 1-2 times the subcutaneous phase 3 dose, no clinically significant pharmacokinetic interactions were found, and the combination was well tolerated.[8]
Two interactions did reach clinical significance in the broader program. Bremelanotide reduced plasma concentrations of indomethacin and naltrexone.[1] The naltrexone interaction is particularly relevant because naltrexone is used in alcohol dependence treatment, and the two patient populations can overlap. The mechanism appears to involve slowed gastric emptying reducing absorption of orally administered drugs.
Serious Adverse Events and Mortality
No deaths occurred across the entire bremelanotide clinical development program.[1] A few subjects experienced serious adverse events, but these were rare and not concentrated in any organ system. Clayton et al. (2022) reported that serious adverse events occurred at similar rates in the bremelanotide and placebo groups during the double-blind phase, suggesting no drug-related signal for severe outcomes.[1]
In the 52-week open-label extension, the only severe treatment-emergent adverse event reported by more than one participant was nausea.[3] No new safety signals emerged during extended use, which is reassuring but comes with the caveat that the extension enrolled a self-selected group of women who had tolerated the drug during the core phase. Women who experienced intolerable nausea or other adverse events during the 24-week double-blind period were unlikely to enroll in the extension, creating a selection effect that makes the long-term data appear safer than it might be for the full initial population.
Liver safety has received some attention. The NCBI LiverTox database notes that bremelanotide has been reported to cause mild serum enzyme elevations during therapy and has been implicated in rare instances of clinically apparent acute liver injury. These cases were few and did not lead to a hepatotoxicity warning on the label, but liver function monitoring may be warranted with prolonged use.
The Dropout Problem
The safety data cannot be read in isolation from the dropout data. In the double-blind phase, 30% of the bremelanotide group discontinued versus 13% on placebo.[1] In the open-label extension, only 272 of 684 enrollees (39.8%) completed 52 weeks.[3]
Spielmans (2021) reanalyzed the phase 3 trial data and raised concerns about how these dropouts affect interpretation. Subjects who discontinue due to adverse events or lack of efficacy are not captured in the final efficacy analyses in the same way as completers, and the high dropout rate introduces survivorship bias into both the safety and efficacy conclusions.[9]
Spielmans and Ellefson (2024) followed up with a broader critique, noting that the overall clinical benefit appeared modest when set against the adverse event burden. They described the efficacy as "small effects, questionable outcomes" and questioned whether the risk-benefit ratio justified approval.[10]
Mintzes, Tiefer, and Cosgrove (2021) made a related argument from a regulatory perspective, comparing bremelanotide to flibanserin and arguing that both approvals reflected "the fallacy of regulatory precedent" rather than robust evidence of clinical benefit.[11]
These critiques do not dispute the adverse event data itself. They dispute whether the demonstrated benefits justify those adverse events. That is a separate question, but the safety profile becomes harder to accept when the efficacy signal is debated.
Body Weight Effects
Bremelanotide activates melanocortin 4 receptors (MC4R), which play a central role in appetite regulation. Spana, Jordan, and Fischkoff (2022) published data from two phase 1 randomized controlled trials in obese premenopausal women showing that bremelanotide reduced caloric intake by approximately 400 kcal/day and produced significantly greater weight loss than placebo (least squares mean difference: -1.3 kg over 16 days).[12]
This weight effect was not the target of drug development and has not been pursued in later trials, but it illustrates that bremelanotide's pharmacology extends beyond sexual function. Whether the nausea itself contributes to reduced caloric intake (as it does with GLP-1 agonists) versus direct MC4R-mediated appetite suppression is not fully resolved.
What the Label Says vs. What the Data Show
The FDA label for Vyleesi limits use to no more than 1 dose in 24 hours and no more than 8 doses per month. It lists contraindications for uncontrolled hypertension and cardiovascular disease. It warns about hyperpigmentation that may not resolve.[5]
What the label does not emphasize: the 30% dropout rate, the survivorship bias in the extension data, or the fact that the clinical program was overwhelmingly limited to white American women of a specific age range. The safety profile of bremelanotide in men, postmenopausal women, or diverse ethnic populations comes from much smaller datasets or no data at all.
Off-label use of bremelanotide and its precursor Melanotan II is common in contexts well outside the studied population. The adverse event data from the FDA program applies specifically to 1.75 mg subcutaneous doses in premenopausal women. Extrapolating those rates to different doses, routes, populations, or compounded formulations of unknown purity introduces uncertainty the clinical data cannot address.
The label also recommends discontinuation after 8 weeks without benefit.[5] This is a practical acknowledgment that many women will not respond, and continued exposure to adverse events in non-responders serves no therapeutic purpose. The 8-week cutoff has not been rigorously validated in a dedicated study, but it reflects the timeline over which the phase 3 data showed separation from placebo.
For a deeper look at how bremelanotide works at the central nervous system level, including the melanocortin pathways that explain both its desired effects and its adverse event profile, the mechanism of action article covers the neurobiology in detail. The broader landscape of peptide therapeutics for female sexual dysfunction provides context for where bremelanotide fits relative to other approaches.
The Bottom Line
Bremelanotide's FDA safety dataset is large (3,500 subjects, 43 studies) and shows a consistent pattern: high nausea rates (40%), transient blood pressure elevation, dose-dependent hyperpigmentation risk, and no deaths or concentrated serious adverse events. The tolerability profile drove a 30% dropout rate in pivotal trials. Whether these adverse events are acceptable depends entirely on how one weighs the efficacy evidence, which remains debated in the literature.